Topical post-herpetic neuralgia treatment fails to meet primary endpoint in Phase II

Teva Pharmaceuticals (NYSE:TEVA) and Xenon Pharmaceuticals (NSDQ:XENE) said this week that the Phase II study of a topical post-herpetic neuralgia treatment did not meet its primary or secondary endpoints.

The small-molecule inhibitor, TV-45070, was licensed by Xenon to Teva in December 2012.

Get the full story at our sister site, Drug Delivery Business News.

The post Topical post-herpetic neuralgia treatment fails to meet primary endpoint in Phase II appeared first on MassDevice.

from MassDevice http://ift.tt/2tZRmWB